⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407722 | 0.79 | TSHR (0.35) | — | |
| SCHEMBL455667 | 0.77 | — | — | |
| SCHEMBL184366 | 0.73 | — | — | |
| SCHEMBL351688 | 0.73 | — | — | |
| SCHEMBL28407972 | 0.73 | — | — | |
| SCHEMBL407833 | 0.73 | — | — | |
| SCHEMBL9659680 | 0.73 | — | — | |
| SCHEMBL1357341 | 0.73 | — | — | |
| SCHEMBL767603 | 0.73 | — | — | |
| SCHEMBL7194431 | 0.72 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118265702-A | Microbiocidal isonicotinamide derivatives | 先正达农作物保护股份公司 | 2024-06-28 | — | — | CN | claimed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | claimed |
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | claimed |
| WO-2023089049-A2 | MICROBIOCIDAL ISONICOTINIC AMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-05-25 | — | — | WO | claimed |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-01-20 | — | — | US | claimed |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-09-07 | — | — | US | claimed |
| EP-3856348-A1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS | Incyte Corporation (US) | 2021-08-04 | — | — | EP | claimed |
| US-20040171607-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-09-02 | — | — | US | claimed |
| CN-1525972-A | Hetero-bicyclic crf antagonists | — | 2004-09-01 | — | — | CN | claimed |
| EP-1425281-A1 | CHEMICAL COMPOUNDS | SB PHARMCO PUERTO RICO INC. CSC, The United States Corporation Company (PR) | 2004-06-09 | — | — | EP | claimed |
| EP-1425280-A2 | HETERO-BICYCLIC CRF ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-06-09 | — | — | EP | claimed |
| US-6620839-B2 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2003-09-16 | — | — | US | claimed |
| WO-2003059341-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | claimed |
| WO-2003008412-A2 | HETERO-BICYCLIC CRF ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2003-01-30 | — | — | WO | claimed |
| WO-2003008414-A1 | CHEMICAL COMPOUNDS | SB PHARMCO PUERTO RICO INC. (PR) | 2003-01-30 | — | — | WO | claimed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | claimed |
| EP-0031708-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR | ICI PHARMA (FR) | 1984-06-13 | — | — | EP | claimed |